| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.39 | 0.03 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.03 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.083 | 0.04 |